IDEAS home Printed from https://ideas.repec.org/a/spr/drugsa/v47y2024i7d10.1007_s40264-024-01427-3.html
   My bibliography  Save this article

The Safety of Ixekizumab in Chinese Adults with Moderate-to-Severe Plaque Psoriasis: Analyses from a Prospective, Single-Arm, Multicenter, 12-Week Observational Study

Author

Listed:
  • Ying Li

    (Tongji University School of Medicine)

  • Lin Dang

    (Longgang Central Hospital of Shenzhen)

  • Chengzhi Lv

    (Dalian Skin Disease Hospital)

  • Bingjiang Lin

    (Ningbo First Hospital)

  • Juan Tao

    (Wuhan Union Hospital Tongji Medical College Huazhong University of Science and Technology)

  • Nan Yu

    (General Hospital of Ningxia Medical Hospital)

  • Ya Deng

    (The Second Hospital Affiliated to Chongqing Medical University)

  • Huiping Wang

    (Tianjin Medical University General Hospital)

  • Xiaojing Kang

    (People’s Hospital of Xinjiang Uygur Autonomous Region)

  • Hui Qin

    (Tongji University School of Medicine)

  • Rong Chen

    (Eli Lilly and Company)

  • Jinnan Li

    (Eli Lilly and Company)

  • Yunsheng Liang

    (Southern Medical University)

  • Yanhua Liang

    (Southern Medical University)

  • Yuling Shi

    (Tongji University School of Medicine)

Abstract

Introduction Ixekizumab, a monoclonal antibody against interleukin-17A, is efficacious and well tolerated for the treatment of moderate-to-severe plaque psoriasis. However, there are limited data on the real-world safety of ixekizumab in Chinese patient populations. We performed an observational study of ixekizumab for the treatment of moderate-to-severe plaque psoriasis in routine clinical practice in China. Here we present a further safety analysis of this study. Methods In this prospective, observational, single-arm, multicenter, post-marketing safety study, adults (≥18 years) with moderate-to-severe plaque psoriasis receiving ixekizumab were enroled at dermatology departments in hospitals across China and prospectively followed for 12 weeks or until their last dose of ixekizumab. In this analysis, we evaluated adverse events (AEs) of special interest (AESIs) identified using MedDRA® search strategies. We also analyzed AEs and AESIs occurring in greater than ten patients in subgroups by age (

Suggested Citation

  • Ying Li & Lin Dang & Chengzhi Lv & Bingjiang Lin & Juan Tao & Nan Yu & Ya Deng & Huiping Wang & Xiaojing Kang & Hui Qin & Rong Chen & Jinnan Li & Yunsheng Liang & Yanhua Liang & Yuling Shi, 2024. "The Safety of Ixekizumab in Chinese Adults with Moderate-to-Severe Plaque Psoriasis: Analyses from a Prospective, Single-Arm, Multicenter, 12-Week Observational Study," Drug Safety, Springer, vol. 47(7), pages 711-719, July.
    • Handle: RePEc:spr:drugsa:v:47:y:2024:i:7:d:10.1007_s40264-024-01427-3
    DOI: 10.1007/s40264-024-01427-3
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40264-024-01427-3
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s40264-024-01427-3?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:drugsa:v:47:y:2024:i:7:d:10.1007_s40264-024-01427-3. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com/economics/journal/40264 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.